Intensity Therapeutics(INTS) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Shelton, Conn., August 7, 2025 – Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces second quarter ...